Siemens Healthineers AG Announces Strategic Collaboration with Novo for Metabolic Dysfunction‑Associated Steatotic Liver Disease (MASLD) and Metabolic‑Associated Steatohepatitis (MASH)

Clinical Context and Rationale

Metabolic dysfunction‑associated steatotic liver disease (MASLD) encompasses a spectrum of hepatic pathology ranging from benign steatosis to the progressive form known as metabolic‑associated steatohepatitis (MASH). Recent epidemiological studies indicate that up to 25 % of the adult population in high‑income countries harbors hepatic steatosis, with approximately 5–10 % progressing to MASH and ultimately cirrhosis or hepatocellular carcinoma. Early identification of fibrosis risk is therefore a critical clinical objective, as intervention at the stage of early fibrosis can halt or reverse disease progression.

The Enhanced Liver Fibrosis (ELF) test represents the first U.S.‑authorized blood‑based assay capable of quantitatively assessing liver fibrosis risk in MASH patients. The assay measures a composite panel of serum biomarkers—procollagen type III N‑terminal peptide (PIIINP), hyaluronic acid, and tissue inhibitor of metalloproteinases‑1 (TIMP‑1)—to generate a fibrosis score. Validation studies demonstrate an area under the receiver operating characteristic curve (AUROC) of 0.82–0.90 for detecting clinically significant fibrosis (≥F2) versus non‑fibrotic controls, with a sensitivity of 88 % and specificity of 70 % at the optimal cut‑point. Importantly, the test has been cleared for clinical use under the U.S. Food and Drug Administration (FDA) 510(k) pathway, and a current Clinical Laboratory Improvement Amendments (CLIA)‑certified laboratory network provides widespread availability.

Partnership Objectives and Implementation Strategy

The Siemens‑Novo partnership is structured around four principal objectives:

  1. Disease Awareness – Joint educational campaigns targeting hepatology, gastroenterology, and primary care communities will highlight the prevalence of MASLD/MASH, the limitations of current imaging modalities, and the role of early fibrosis assessment.
  2. Early Assessment – Integration of the ELF test into existing clinical workflows will facilitate risk stratification of patients with metabolic risk factors (e.g., type 2 diabetes, obesity) and streamline referral pathways for specialized care.
  3. Expanded Access – Siemens Healthineers will leverage its global laboratory services to broaden distribution of the ELF test, ensuring coverage through national laboratory networks and securing reimbursement pathways. The test’s coverage under the CPT code 82565 enhances payer acceptance, reducing cost barriers for clinicians.
  4. Non‑Invasive Diagnostics – By providing a reliable alternative to liver biopsy and elastography, the ELF test reduces procedure‑related adverse events. Current safety data report no serious adverse events associated with the blood draw, and the test’s non‑invasive nature eliminates the risk of bleeding, infection, or sampling error inherent to biopsy.

From a regulatory perspective, Siemens Healthineers has confirmed that the ELF test is compliant with both U.S. and European regulatory frameworks. The assay’s FDA 510(k) clearance was obtained in 2020, and it has received CE marking for use in the European Economic Area (EEA). The collaboration will also explore the potential for accelerated regulatory approval of adjunctive indications, such as monitoring disease progression in clinical trials and evaluating therapeutic response to novel antifibrotic agents.

Share‑Buyback Program Update

In addition to its clinical initiatives, Siemens Healthineers has disclosed an active share‑buyback program, underscoring the company’s confidence in its financial positioning and shareholder value proposition. Between 14 and 20 September 2026, the company repurchased approximately 90 000 shares, bringing the cumulative repurchased volume since the program’s launch on 1 June 2026 to roughly 3.2 million shares. These transactions were executed on the Frankfurt Stock Exchange’s electronic trading platform under a credit‑institution arrangement, adhering to the exchange’s regulatory requirements and ensuring transparent market conduct.

The buyback is part of a broader strategy to optimize the capital structure, with anticipated effects on earnings per share (EPS) and return on equity (ROE). While the immediate market impact has been modest—reflective of routine trading dynamics within the DAX—the program demonstrates Siemens Healthineers’ commitment to returning capital to shareholders without compromising investment in research and development.

Strategic Alignment and Market Implications

The liver disease diagnostics initiative dovetails with Siemens Healthineers’ overarching strategy to expand its diagnostic portfolio, particularly in clinical chemistry and immunoassay domains. By integrating advanced fibrosis testing into its suite of products, the company positions itself at the forefront of precision diagnostics for chronic liver disease—a field experiencing rapid growth due to rising metabolic syndrome prevalence and the emergence of novel pharmacotherapies.

From a healthcare system perspective, the adoption of the ELF test offers several practical benefits:

  • Cost‑effectiveness: Reduced need for liver biopsies and imaging studies can lower overall diagnostic costs.
  • Patient safety: Non‑invasive testing mitigates procedure‑related complications.
  • Clinical decision‑making: Earlier detection of fibrosis risk informs timely therapeutic interventions and lifestyle modifications.

The collaboration with Novo—an organization with a strong pipeline of metabolic disease therapeutics—also paves the way for future integrated diagnostics‑therapeutics approaches, potentially enabling companion diagnostics for emerging MASH treatments.

Conclusion

Siemens Healthineers AG’s partnership with Novo to promote early, non‑invasive detection of fibrosis in MASLD and MASH patients represents a clinically significant advance. By leveraging the FDA‑cleared ELF test, the collaboration addresses a clear unmet need in liver disease diagnostics, aligns with regulatory frameworks, and delivers tangible benefits for patients, clinicians, and healthcare systems. Concurrently, the company’s share‑buyback activity reflects a balanced financial strategy, reinforcing shareholder confidence while continuing to invest in innovative diagnostics solutions.